[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627117":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":33,"centralContacts":38,"locations":43,"responsibleParty":62,"collaborators":26,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":26,"eligibilityCriteria":72,"healthyVolunteers":73,"sex":74,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":26,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":88,"overallStatus":94,"whyStopped":26,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"Central South University","OTHER",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with schizophrenia","EXPERIMENTAL","One hundred patients with schizophrenia (SZ) who are either drug-naïve at first episode or have relapsed after discontinuing medication for more than one month will be enrolled.\n\nBefore treatment, all participants will undergo demographic and clinical assessments, along with structural and resting-state functional magnetic resonance imaging (MRI) scans.\n\nAfter the baseline MRI scan, patients will receive repetitive transcranial magnetic stimulation (rTMS) targeting the dorsolateral prefrontal cortex (dlPFC). Upon completion of the treatment course, clinical assessments and MRI scans will be repeated.",[13],"Device: repetitive transcranial magnetic stimulation (rTMS)",{"label":15,"type":10,"description":16,"interventionNames":17},"Patients with bipolar disorder","One hundred patients with bipolar disorder who are either drug-naïve at first episode or have relapsed after discontinuing medication for more than one month will be enrolled.\n\nBefore treatment, all participants will undergo demographic and clinical assessments, along with structural and resting-state functional magnetic resonance imaging (MRI) scans.\n\nAfter the baseline MRI scan, patients will receive repetitive transcranial magnetic stimulation (rTMS) targeting the dorsolateral prefrontal cortex (dlPFC). Upon completion of the treatment course, clinical assessments and MRI scans will be repeated.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Patients with major depressive disorder","One hundred patients with major depressive disorder who are either drug-naïve at first episode or have relapsed after discontinuing medication for more than one month will be enrolled.\n\nBefore treatment, all participants will undergo demographic and clinical assessments, along with structural and resting-state functional magnetic resonance imaging (MRI) scans.\n\nAfter the baseline MRI scan, patients will receive repetitive transcranial magnetic stimulation (rTMS) targeting the dorsolateral prefrontal cortex (dlPFC). Upon completion of the treatment course, clinical assessments and MRI scans will be repeated.",[13],{"label":23,"type":24,"description":25,"interventionNames":26},"healthy controls","NO_INTERVENTION","One hundred healthy controls will be enrolled. Before the baseline assessment, all participants will undergo demographic and clinical evaluations, along with structural and resting-state functional magnetic resonance imaging (MRI) scans. Healthy controls will undergo clinical assessments and MRI scans at corresponding time points without receiving rTMS treatment.",null,[28],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":26},"DEVICE","repetitive transcranial magnetic stimulation (rTMS)","Patients will receive repetitive transcranial magnetic stimulation (rTMS) targeting the dorsolateral prefrontal cortex (dlPFC).",[15,19,9],[34],{"name":35,"affiliation":36,"role":37},"Wenbin Guo, Ph.D.","Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha 410011, Hunan, China.","STUDY_CHAIR",[39],{"name":35,"role":40,"phone":41,"phoneExt":26,"email":42},"CONTACT","+8673185360921","guowenbin76@csu.edu.cn",[44],{"facility":45,"status":26,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Second Xiangya Hospital","Changsha","Hunan","410011","China","CN",{"type":52,"coordinates":53},"Point",[54,55],112.97087,28.19874,{"lat":55,"lon":54},[58],{"name":59,"role":40,"phone":60,"phoneExt":26,"email":61},"haohao Yan, Ph.D.","86+073185360921","yanhaohao1995@gmail.com",{"type":63,"investigatorFullName":64,"investigatorTitle":65,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Guo Wenbin","Professor","100627117","brain-network-mechanisms-of-cognitive-impairments-in-major-psychiatric-disorders-and-their-clinical-applications-100627117",false,"NCT07444463","Brain Network Mechanisms of Cognitive Impairments in Major Psychiatric Disorders and Their Clinical Applications","Study on the Brain Network Mechanisms of Cognitive Impairments in Major Psychiatric Disorders and Their Application in Cognitive Assessment, Diagnosis, and Precision Treatment","Inclusion Criteria:\n\n* 1, For Patients (SZ, BD, MDD):\n\nDiagnosis of schizophrenia (SZ), bipolar disorder (BD), or major depressive disorder (MDD) according to standard diagnostic criteria\n\nFirst-episode drug-naïve patients or patients who have relapsed after discontinuing medication for more than one month\n\nAged 18-60 years\n\nCompletion of at least 6 years of formal education\n\n2, For Healthy Controls:\n\nAged 18-60 years\n\nCompletion of at least 6 years of formal education\n\nNo current or past psychiatric disorders\n\nNo first-degree relatives with psychiatric disorders\n\nNo history of treatment with psychotropic medications or physical therapy for psychiatric disorders\n\nExclusion Criteria:\n\n* Prior use of psychotropic medications or receipt of physical treatment for psychiatric disorders (for patient group)\n\nContraindications to MRI scanning\n\nHistory of brain injury\n\nHistory of substance abuse\n\nPresence of other neurological disorders\n\nPresence of severe medical or systemic physical illnesses.",true,"ALL","18 Years","60 Years",{"count":78,"type":79},400,"ESTIMATED","INTERVENTIONAL",[82],"NA","Previous and our studies have shown that cognitive impairments are core symptoms of three major psychiatric disorders-schizophrenia, bipolar disorder, and major depressive disorder, and are associated with underlying brain dysfunction. However, the specific brain networks involved in cognitive impairments (cognitive impairment brain networks) in these disorders, as well as whether their neuroimaging features can be applied to cognitive assessment, diagnosis, and precision treatment, remain unclear. This study aims to identify cognitive impairment brain networks using publicly available large-scale datasets and clinical research, and to explore whether the neuroimaging features of these networks can be utilized for cognitive assessment, diagnosis, and treatment response prediction. First, a \"sensitive cognitive assessment model for major psychiatric disorders\" will be established through meta-analysis based on sensitive scales. Second, cognitive impairment brain networks will be identified using publicly available large-scale datasets combined with the lesion network mapping method, and their validity will be examined by assessing their non-randomness, reproducibility, symptom specificity, and disease specificity. Third, cognitive assessment and diagnostic models will be developed based on neuroimaging features of these networks. Finally, a combination of cross-sectional and longitudinal study designs will be used in a clinical trial to validate the identified networks and models, and a treatment response prediction model will be established based on the neuroimaging features of cognitive impairment brain networks. This study will advance the understanding of the neurophysiological mechanisms underlying cognitive impairment in major psychiatric disorders, promote the application of neuroimaging in psychiatric diagnosis and treatment, and improve traditional diagnostic, therapeutic, and cognitive assessment approaches.",[85,86,87],"Schizophrenia","Bipolar Disorder","Major Depressive Disorder (MDD)",[89,90,91,92,93],"schizophrenia","cognitive impairments","brain imaging","bipolar disorder","major depressive disorder","NOT_YET_RECRUITING","2026-03-02",{"date":97,"type":98},"2026-03-04","ACTUAL",{"date":100,"type":79},"2027-01-01",{"date":102,"type":79},"2029-12-31",{"name":5,"class":6},1]